CTLA4 and melanoma: Therapeutic targeting of immune checkpoints such as programmed death-ligand 1, programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) with ICIs has revolutionized the treatment of advanced melanoma.